To the central content area
Securities firms reward program (until 2021/12/31) Bond ETFs Investors Reward Program (2021 H2) (until 2021/12/31) ETN Investors Reward Program (2021 H2) (until 2021/12/31) 2021 Education Saminars (until 2021/11/18)
:::Listed Companies > Listed Companies Info. > Main Board Companies > Listed Company Profile

General Stock Board Listed Company Profile

4152 TLC
Company Profile
Chairman CEO Spokesperson Tel Address Date of Listing (Regular)
Keelung Hong George Yeh Yunlong Tseng 26557377 11F-1,No 3,Yuanqu St.,Nangang DistTaipei City, 11503 Taiwan. R.O.C. 2012/12/21
Industry Main Business
Biotechnology and Medical Care Taiwan Liposome Company (TLC) is a biopharmaceutical company focused on the research, development and commercialization of innovative pharmaceutical products based on its proprietary drug delivery technologies. Our strengths lie in lipid-based formulation and scale-up for parenteral drugs using micelles and nanoparticles to optimize the pharmacokinetics of drugs for better efficacy and lower toxicity, and thus prolong the product lifecycle of branded drugs.
Market Information ( 2021/09/16 )
Shr. Vol. Highest Lowest Closed Change Transaction TurnOver(%) long
53.34 99.80  99.50  99.50  -0.50  50 0.06 N/A N/A
Trading method Fun
price or
on T day
Announcement of Irregularity
TPEx measures
With warrants Can be shorted or margined? Detail
變更交易(分盤) Y N N N N Today History
Financial Reports
Cash Flows Items
(NT$ thousand)
Cash flows from operating activities
Cash flows from investing activities
Cash flows from financing activities
Current assets
Non-current assets
Total assets
Current liabilities
Non-current liabilities
Total liabilities
Share capital
Capital surplus
Retained earnings
Other equity interest
Treasury shares
Total equity attributable to owners of parent
Non-controlling interests
Total equity
Book Value per share(NT$)
Comprehensive Income Operating revenue
Operating costs
Gross profit from operations
Operating expenses
Net other income (expenses)
Net operating income
Non-operating income and expenses
Profit before tax
Tax expense
Profit from continuing operations
Profit from discontinued operations
Other comprehensive income
Comprehensive income
Basic earnings per share
* Auditor's report on latest financial statements: auditor's report:
* More detail:MOPS
* Foreign issuers’ information is disclosed in consolidated statements.